Apretop Kit

Introduction

Apretop is a prescription medication that combines the active ingredients Aprepitant and Aprepitant. It is available in the form of a kit, which includes both oral capsules and an injectable solution.

Uses

Apretop is primarily prescribed to prevent and treat nausea and vomiting caused by chemotherapy in patients undergoing cancer treatment. It is used in combination with other antiemetic medications to provide effective relief.

Dosage and Administration

The dosage of Apretop may vary depending on the specific chemotherapy regimen and the patient’s individual needs. Follow the instructions provided by your healthcare professional.

For the oral capsules, the usual recommended dose is 125 mg taken orally one hour before chemotherapy, followed by 80 mg taken once daily for the next two days. Take the capsules with or without food, as directed by your doctor.

For the injectable solution, it is administered by a healthcare professional as a single intravenous dose of 150 mg within 30 minutes prior to chemotherapy.

Mechanism of Action

The active ingredients in Apretop, Aprepitant and Aprepitant, work by blocking a specific substance in the brain called substance P. Substance P is known to play a role in triggering nausea and vomiting. By blocking substance P, Apretop helps to prevent and reduce chemotherapy-induced nausea and vomiting.

Side Effects

Common side effects may include fatigue, constipation, diarrhea, headache, and hiccups. These side effects are usually mild and temporary.

However, if you experience any of the following serious side effects, contact your healthcare professional immediately:

• Allergic reactions such as rash, itching, swelling, severe dizziness, or difficulty breathing
• Severe stomach pain or vomiting
• Changes in liver function, such as yellowing of the skin or eyes, dark urine, or persistent nausea

Drug Interactions

Apretop may interact with other medications, including certain antidepressants, antifungal drugs, and HIV medications. Inform your healthcare professional about all the medications you are taking, including prescription, over-the-counter, and herbal products, to avoid potential drug interactions. Your healthcare professional can determine if any adjustments to your medication regimen are necessary.

Precautions

Before taking Apretop, inform your healthcare professional if you have any allergies, liver problems, or if you are pregnant or breastfeeding. Apretop should be used with caution in patients with moderate to severe liver impairment.

This medication may interact with certain medications, including birth control pills, blood thinners, and corticosteroids. Discuss all your current medications with your healthcare professional to avoid potential interactions.

Storage

Apretop should be stored at room temperature, away from moisture and heat. Keep the medication out of the reach of children and pets. Do not use the medication if it has expired or if the packaging is damaged.

Patient Tips

• Follow the dosage instructions provided by your healthcare professional.
• If you miss a dose, contact your healthcare professional for further guidance.
• Avoid consuming alcohol while taking Apretop, as it may increase the risk of certain side effects.
• If you experience any unusual or persistent symptoms, notify your healthcare professional.
• Keep a record of any side effects you experience and discuss them with your healthcare professional during follow-up appointments.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Aprepitant 125 mg hard capsules (Health Professionals SmPC) Available at:
• Aprepitant (Drugs.com) [Accessed 0 Jun. 2024] (online) Available at:
• aprepitant (RX) [Accessed 26 Jun. 2024] (online) Available at:
• Aprepitant (MedlinePlus) [Accessed 17 Jun. 2024] (online) Available at:
• Vazirian F, Samadi S, Rahimi H, Sadeghi M, Mohammadpour AH. Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review. Cancer Chemother Pharmacol. 2022 Jul;90(1):1-6. doi: 10.1007/s00280-022-04439-x. Epub 2022 May 30. [Accessed 4 Jun. 2024] Available at: